Full-Time

Senior Director

Global Regulatory Affairs, Chemistry Manufacturing Controls, CMC

Confirmed live in the last 24 hours

Eikon Therapeutics

Eikon Therapeutics

201-500 employees

Biotech startup developing innovative medicines

Compensation Overview

$239k - $261.3k/yr

+ Bonus + Equity Compensation

Expert

New York, NY, USA

This role will require a minimum of 3 days a week of onsite presence in our Jersey City (NJ) office.

Category
Risk & Compliance
Legal & Compliance
Biology & Biotech
Connection
Connection
Connection
logo

Get referrals →

You have ways to get a Eikon Therapeutics referral from your network.

💡

Applications through a referral are 3x more likely to get an interview!

Requirements
  • Post Graduate degree with 12+ years of experience or a Bachelor's degree with 15+ years of experience in a relevant experience in regulatory affairs, with a focus on CMC aspects of pharmaceutical products.
  • Experience in Biologics
  • Successful experience leading Regulatory CMC activities for multiple regulatory filings in pre-and post-approval settings, including experience filing an NDA/MAA for an NCE
  • Excellent oral and written communication skills with proven ability to analyze and organize information logically
  • Thorough knowledge of drug development, health authority regulations and guidelines, CMC and Quality documentation standards, with the ability to apply knowledge to guide the delivery of regulatory documents efficiently
  • Strong leadership and project management skills, ability to work independently, multi-task, and work effectively under pressure
  • Excellent interpersonal, active listening, and influencing skills
  • Strong collaboration, teamwork, organizational skills, and attention to detail
Responsibilities
  • Collaborate and partner closely with CMC colleagues to develop CMC global regulatory submission strategies, complete content review, assure compliance with regulatory standards and health authority guidance while maintaining submission timelines to meet business objectives
  • Plan and track the completion of CMC content for IND/CTA submissions while ensuring company template content conforms with regulatory requirements
  • Coordinate responses to CMC information requests from health authorities
  • Ensure that appropriate documented quality control (QC) checks are performed for CMC documents before health authority submission and respond to findings, and recommend process improvements as needed
  • Collaborate with CMC Team and Quality to ensure regulatory conformance of technical documentation, including technical transfer protocols, validation protocols, and technical reports, manufacturing and packaging/labeling information
  • Ensure communication and alignment on CMC regulatory strategy through partnership and communication with internal key stakeholders
  • Proactively identify potential risks to programs and contribute to solutions to keep assigned programs on track while maintaining high-quality
  • Ensure that CMC-related changes are reported to authorities per regulatory requirements
  • Responsible for regulatory impact assessments for CMC change control
  • Lead preparation for health authority meetings with CMC focus and participate in multidisciplinary efforts to prepare CMC updates to regulatory documents including, Investigator Brochures, Annual Reports, and briefing documents for health authority meetings
  • Work closely with the regulatory operations group to ensure proper archival of CMC- related Health Authority correspondence, regulatory commitments and Agency reporting obligations for the organization
  • Maintain knowledge of current and emerging CMC regulatory requirements, guidelines, and best practices, and effectively communicate relevant topics to colleagues
  • Oversee responsibilities for department staff and vendors as agreed with the manager
Desired Qualifications
  • Prior management experience preferred

Eikon Therapeutics develops new medicines in the pharmaceutical industry by studying biological systems to identify drug targets. They utilize a proprietary single-molecule tracking platform to visualize protein movements in living cells, combined with artificial intelligence and automation for precise analysis of molecular interactions. Their diverse team integrates science and engineering to create therapies aimed at improving the lives of patients with serious diseases. Eikon's goal is to explore cell and molecular biology in innovative ways to develop effective treatments.

Company Size

201-500

Company Stage

Series D

Total Funding

$1.1B

Headquarters

Hayward, California

Founded

2019

Simplify Jobs

Simplify's Take

What believers are saying

  • Eikon raised $350.7 million in Series D funding, boosting clinical-stage programs.
  • The company is advancing Phase 3 cancer treatments, including melanoma immunotherapy.
  • Strong investor confidence is evident with backing from Lux Capital and Soros Capital.

What critics are saying

  • Intellectual property disputes may arise over single-molecule tracking technology.
  • High valuation could attract regulatory scrutiny and financial compliance issues.
  • Significant real estate investments pose financial risks if growth projections falter.

What makes Eikon Therapeutics unique

  • Eikon uses proprietary single-molecule tracking for real-time protein movement analysis.
  • The company integrates AI and advanced automation in drug discovery processes.
  • Eikon's diverse team combines expertise in biology, engineering, and chemistry.

Help us improve and share your feedback! Did you find this helpful?

Benefits

401(k) Company Match

Medical (premiums covered by Eikon at 95%)

Dental Insurance

Vision Insurance

Mental Health Support

Unlimited Paid Time Off

Paid Holidays

Life Insurance

Enhanced Parental Leave

Daily subsidized lunch program

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

1%

2 year growth

3%
BioSpace
Mar 14th, 2025
Nurix Therapeutics Appoints Drug Development Expert Roy D. Baynes, MB.Bch., M.Med., Ph.D., to Its Board of Directors

Dr. Baynes, who currently serves as executive vice president and chief medical officer of Eikon Therapeutics, has had a distinguished career in hematology and oncology and over 22 years of clinical leadership experience in pharmaceutical and biotech companies.

Chronicles Magazine
Mar 3rd, 2025
Family office investors demonstrate appetite for innovation and diversity

Another significant entity, Soros Capital - managed by Robert Soros, son of the billionaire George Soros - participated in a $350.7 million financing round for Eikon Therapeutics.

Business Wire
Feb 27th, 2025
Eikon Therapeutics Secures $350.7 Million Series D to Advance Clinical-Stage Programs and Future Pipeline

Eikon Therapeutics, Inc., a pivotal-stage biotechnology company that integrates advanced engineering with cutting-edge molecular and cell biology to a

Stat News
Feb 26th, 2025
Eikon Therapeutics raises $350 million

Eikon Therapeutics, led by former Merck RD head Roger Perlmutter, raised $350 million, bringing its total funding to $1.1 billion. The funds will support the clinical development of cancer drugs, including an immunotherapy in Phase 3 for melanoma and two PARP inhibitors. The financing round included investors like Lux Capital and Alexandria Venture Investments.

BioWorld
Feb 26th, 2025
Eikon raises $350.7M in Series D

Eikon Therapeutics Inc. has closed a $351 million series D funding round, marking the largest venture capital round of 2025 and the first series D of the year. This funding supports Eikon as it enters phase III in cancer treatment development.